489 related articles for article (PubMed ID: 30396745)
1. PD-1 immunobiology in systemic lupus erythematosus.
Curran CS; Gupta S; Sanz I; Sharon E
J Autoimmun; 2019 Feb; 97():1-9. PubMed ID: 30396745
[TBL] [Abstract][Full Text] [Related]
2. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus infection induces lupus autoimmunity.
Harley JB; James JA
Bull NYU Hosp Jt Dis; 2006; 64(1-2):45-50. PubMed ID: 17121489
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus.
Poole BD; Templeton AK; Guthridge JM; Brown EJ; Harley JB; James JA
Autoimmun Rev; 2009 Feb; 8(4):337-42. PubMed ID: 19167523
[TBL] [Abstract][Full Text] [Related]
5. The key player in the pathogenesis of environmental influence of systemic lupus erythematosus: Aryl hydrocarbon receptor.
Wu J; Pang T; Lin Z; Zhao M; Jin H
Front Immunol; 2022; 13():965941. PubMed ID: 36110860
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus and systemic lupus erythematosus.
Draborg AH; Duus K; Houen G
Clin Dev Immunol; 2012; 2012():370516. PubMed ID: 22811739
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus and systemic lupus erythematosus.
James JA; Harley JB; Scofield RH
Curr Opin Rheumatol; 2006 Sep; 18(5):462-7. PubMed ID: 16896283
[TBL] [Abstract][Full Text] [Related]
8. MAP4K Family Kinases and DUSP Family Phosphatases in T-Cell Signaling and Systemic Lupus Erythematosus.
Chuang HC; Tan TH
Cells; 2019 Nov; 8(11):. PubMed ID: 31766293
[TBL] [Abstract][Full Text] [Related]
9. Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity.
Tong M; Fang X; Yang J; Wu P; Guo Y; Sun J
Immunol Lett; 2020 Nov; 227():96-101. PubMed ID: 32891685
[TBL] [Abstract][Full Text] [Related]
10. The role of the aryl hydrocarbon receptor (AhR) in modulating intestinal ILC3s to optimise gut pathogen resistance in lupus and benefits of nutritional AhR ligands.
Hanlon N; Gillan N; Neil J; Seidler K
Clin Nutr; 2024 Jun; 43(6):1199-1215. PubMed ID: 38631087
[TBL] [Abstract][Full Text] [Related]
11. The curiously suspicious: a role for Epstein-Barr virus in lupus.
Harley JB; Harley IT; Guthridge JM; James JA
Lupus; 2006; 15(11):768-77. PubMed ID: 17153849
[TBL] [Abstract][Full Text] [Related]
12. AhR-ROR-γt complex is a therapeutic target for MAP4K3/GLK
Chuang HC; Chen YM; Chen MH; Hung WT; Yang HY; Tseng YH; Tan TH
FASEB J; 2019 Oct; 33(10):11469-11480. PubMed ID: 31318609
[TBL] [Abstract][Full Text] [Related]
13. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
[TBL] [Abstract][Full Text] [Related]
14. Systemic lupus erythematosus due to Epstein-Barr virus or Epstein-Barr virus infection provocating acute exacerbation of systemic lupus erythematosus?
Kasapcopur O; Ergul Y; Kutlug S; Candan C; Camcioglu Y; Arisoy N
Rheumatol Int; 2006 Jun; 26(8):765-7. PubMed ID: 16200398
[TBL] [Abstract][Full Text] [Related]
15. Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile.
Chougule D; Nadkar M; Rajadhyaksha A; Pandit-Shende P; Surve P; Dawkar N; Khadilkar P; Patwardhan M; Kaveri S; Ghosh K; Pradhan V
J Med Virol; 2018 Mar; 90(3):559-563. PubMed ID: 28734074
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
17. Potential role of EBV and Toll-like receptor 9 ligand in patients with systemic lupus erythematosus.
Izadi S; Najfizadeh SR; Nejati A; TeimooriRad M; Shahmahmoodi S; Shirazi FG; Shokri F; Marashi SM
Immunol Res; 2023 Oct; 71(5):698-708. PubMed ID: 37097524
[TBL] [Abstract][Full Text] [Related]
18. Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients.
Draborg AH; Sandhu N; Larsen N; Lisander Larsen J; Jacobsen S; Houen G
J Immunol Res; 2016; 2016():6473204. PubMed ID: 27110576
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory effects of indole-3-carbinol on monocyte-derived macrophages in systemic lupus erythematosus: A crucial role for aryl hydrocarbon receptor.
Mohammadi S; Memarian A; Sedighi S; Behnampour N; Yazdani Y
Autoimmunity; 2018 Aug; 51(5):199-209. PubMed ID: 30289282
[TBL] [Abstract][Full Text] [Related]
20. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
